Please login to the form below

Not currently logged in
Email:
Password:

DCVax-L

This page shows the latest DCVax-L news and features for those working in and with pharma, biotech and healthcare.

BMS' Opdivo set for early access in UK

BMS' Opdivo set for early access in UK

Until now, the only PIM granted under the scheme was for Northwest Biotherapeutics' cell-based therapy DCVax-L for a form of brain cancer known as malignant glioma.

Latest news

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
Pharma M&A
Pharma funding and M&A in 2020
Why pharma M&A has continually bucked the trend...
Behaviour change through medical education: How can we turn aspiration into reality?
Practical, evidence-based insights into a CME process that aims to effect measurable behaviour change...

Infographics